Preoperative SGLT2 inhibitors associated with lower mortality after cardiac procedures in propensity-matched cohort.
This retrospective cohort study of 15,052 patients (7,526 matched pairs) undergoing major cardiac procedures compared preoperative SGLT2 inhibitor users to non-users. SGLT2 inhibitor use was associated with reduced all-cause mortality at 30 days (1.3% vs 2.3%, RR 0.566), 90 days (2.2% vs 3.4%, RR 0.643), and 1 year (3.8% vs 5.8%, RR 0.657), and with lower acute kidney injury at 30 days (15.4% vs 17.7%, RR 0.870), but higher hospital readmission rates (76.4% vs 68.7%, RR 1.111).
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 2, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Cohort
- Sample size
- 15,052
- Duration
- 12 months
- Population
- Adults (≥18 years) undergoing cardiac procedures, identified from the TriNetX U.S. Collaborative Network. Propensity score-matched cohorts with mean age 65.8 ± 10.6 years, 70.5% male, 29.5% female.
- Primary outcome
- All-cause mortality at 30 days, 90 days, and 1 year.
- Effect size
- All-cause mortality at 30 days: RR 0.566 [95% CI 0.443-0.722]; at 90 days: RR 0.643 [95% CI not fully specified]; at 1 year: RR 0.657 [95% CI not fully specified]. Acute kidney injury at 30 days: RR 0.870 [95% CI not fully specified]. Hospital admission rates: RR 1.111 [95% CI 1.089-1.133].
- Significance
- Significant
- Journal
- Journal of clinical medicine
- Published
- Sep 2, 2026
Funding: Not reported.
Conflicts: Not reported.
Sources
Primary source
- Journal of clinical medicine ↗Peer reviewed
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.